These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 4580127)

  • 1. [Clinical testing of drugs].
    Elis J
    Cesk Zdrav; 1973; 21(3):126-30. PubMed ID: 4580127
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative performance of equivalent drugs.
    J Indiana State Med Assoc; 1970 May; 63(5):446. PubMed ID: 5447481
    [No Abstract]   [Full Text] [Related]  

  • 3. [Bioavailability, proof of efficacy and their consequences for drug legislation (author's transl)].
    Schnieders B
    Arzneimittelforschung; 1976; 26(1A):158-63. PubMed ID: 947195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug product equivalence--are specifications necessary?
    Bergen JV
    J Am Pharm Assoc; 1972 Jan; 12(1):21-5. PubMed ID: 5007259
    [No Abstract]   [Full Text] [Related]  

  • 5. QUAD routes out inferior drugs.
    Can Hosp; 1973 May; 50(5):58-9. PubMed ID: 4779804
    [No Abstract]   [Full Text] [Related]  

  • 6. Committee for Medicinal Products for Human Use (CHMP) guideline on the choice of the non-inferiority margin.
    ; ;
    Stat Med; 2006 May; 25(10):1628-38. PubMed ID: 16639773
    [No Abstract]   [Full Text] [Related]  

  • 7. [Harmonization of testing drugs for bioequivalence: problems and possible solutions].
    Zherdev VP; Kolyvanov GB; Litvin AA; Sariev AK
    Eksp Klin Farmakol; 2003; 66(2):60-4. PubMed ID: 12962051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An introductory note to CHMP guidelines: choice of the non-inferiority margin and data monitoring committees.
    Brown D; Volkers P; Day S
    Stat Med; 2006 May; 25(10):1623-7. PubMed ID: 16639776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability of drugs (second of two parts).
    Koch-Weser J
    N Engl J Med; 1974 Sep; 291(10):503-6. PubMed ID: 4604153
    [No Abstract]   [Full Text] [Related]  

  • 10. The potential clinical significance of differences in bioavailability.
    Hosp Formul; 1976 Sep; 11(9):484, 487-8. PubMed ID: 10316482
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic non-equivalence.
    Br Med J; 1972 Sep; 3(5827):599-600. PubMed ID: 5071688
    [No Abstract]   [Full Text] [Related]  

  • 12. Should evidence-based proof of drug efficacy be extrapolated to a "class of agents"?
    Furberg CD; Psaty BM
    Circulation; 2003 Nov; 108(21):2608-10. PubMed ID: 14638524
    [No Abstract]   [Full Text] [Related]  

  • 13. [Basic definitions from the field of biopharmacy and pharmacokinetics].
    Krówczyński L; Danek A
    Pol Tyg Lek; 1976 Apr; 31(14):601-2. PubMed ID: 1272953
    [No Abstract]   [Full Text] [Related]  

  • 14. [On the ethics of clinical trials of new drugs].
    Leshchinskiĭ LA
    Klin Med (Mosk); 1999; 77(6):50-1. PubMed ID: 10459222
    [No Abstract]   [Full Text] [Related]  

  • 15. How good are our drugs?
    Miller LC
    Am J Hosp Pharm; 1970 May; 27(5):367-74. PubMed ID: 5422276
    [No Abstract]   [Full Text] [Related]  

  • 16. Bioequivalence and interchangeability of narrow therapeutic range drugs. Canadian Society for Pharmaceutical Sciences discussion.
    Palylyk-Colwell E; Jamali F; Dryden W; Friesen E; Koven S; Mohamed I; Osmond B; Alessi-Severini S; Sheldon L; Sheldon R; Tam Y; Tsuyuki R; Zhanel G
    J Pharm Pharm Sci; 1998; 1(1):2-7. PubMed ID: 10942966
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical testing of drugs].
    Begemann H
    Med Klin; 1973 May; 68(18):569-71. PubMed ID: 4576603
    [No Abstract]   [Full Text] [Related]  

  • 18. Quality drugs and the Saskatchewan formulary.
    Johnson GE
    Can J Hosp Pharm; 1975; 28(3):84-6. PubMed ID: 10316621
    [No Abstract]   [Full Text] [Related]  

  • 19. An introductory note to the CHMP guidelines: choice of the non-inferiority margin and data monitoring committees by David Brown, Peter Volkers and Simon Day, Statistics in Medicine 2006; 25:1623-1627.
    Stat Med; 2007 Jan; 26(1):230-3; author reply 234-5. PubMed ID: 16900566
    [No Abstract]   [Full Text] [Related]  

  • 20. Generic drugs: why all the fuss ... again?
    Williams RL
    Am Pharm; 1986 Sep; NS26(9):21-2, 47. PubMed ID: 3776832
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.